T-MAXIMUM PHARMACEUTICAL

T-MAXIMUM Pharmaceutical (T-MAXIMUM) is a clinical-stage biotech company based in Suzhou, China focusing on the development of allogeneic universal CAR-T cell therapies for solid tumors. It’s core technology platform utilizes a fully proprietary gene-edited immuno-cellular therapy approach. This approach limits the risks of graft-versus-host disease and rejection, allowing allogeneic CAR-T cells persist within the patient's body for an extended period, thereby achieving optimal therapeutic effects with Best-in-Class potential. T-MAXIMUM is currently focusing on advanced-stage malignancies, with its lead pipeline product for recurrent high-grade glioma (rHGG) demonstrating breakthrough efficacy and manageable safety in initial clinical studies and obtained Orphan Drug Designation (ODD) from the US FDA.